NEPH Stock Analysis: Buy, Sell, or Hold?
NEPH - Nephros Inc.
$3.58
0.07 (1.99%)
▲
5d:
+2.29%
30d:
+0.85%
90d:
+16.61%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When NEPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NEPH shows positive signals but monitor for confirmation. Market pricing in 6.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: NEPH shows positive signals but monitor for confirmation. Market pricing in 6.1% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NEPH is currently trading at $3.58, which is considered fair relative to its 30-day fair value range of $3.41 to $3.68. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.2) compared to its historical average (29.2). Remarkably, the market is currently pricing in an annual earnings decline of 6.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NEPH is in a uptrend. Immediate support is located at $3.20, while resistance sits at $3.85.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+70.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NEPH is in a uptrend. Immediate support is located at $3.20, while resistance sits at $3.85.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+70.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.41 -
$3.68
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 70.9% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$3.41 -
$3.68
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.20
Resistance Level
$3.85
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.21
Wall Street Target
$6.00
(+70.9%)
Revenue Growth (YoY)
6.9%
Earnings Growth (YoY)
-80.0%
Profit Margin
4.1%
Valuation Discount vs History
-6.1% cheaper
PE vs Historical
24.2 vs 29.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.1%
(market-implied from PE analysis)
1-Year Target
$3.30
(-6%)
2-Year Target
$3.09
(-12%)
3-Year Target
$2.91
(-17%)
3-Yr Target (if PE normalizes)
(PE: 24→29)
$3.51
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.2, Growth: 262.5%)
$11.85
(+238%)
Base:
(SPY PE: 20.7, Growth: 262.5%)
$10.14
(+189%)
Bear:
(PE: 17.6, Growth: 262.5%)
$8.62
(+146%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (48x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 48.43 | Current EPS (TTM): $0.07
Bull Case
$7.46
(+113%)
Analyst growth 100.0%, PE expands to 53.3
Base Case
$6.78
(+93%)
Market implied 100.0%, PE stable at 48.4
Bear Case
$2.31
(-34%)
Severe decline -20.0%, PE contracts to 41.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.2 to 29.2
Stabilization Target:
$4.23
(+20.6%)
PE Expansion Potential:
+20.6%
Share & Embed Analysis
Last updated: August 04, 2026 9:57 AM ET
Data refreshes hourly during market hours. Next update: 10:57 AM
Data refreshes hourly during market hours. Next update: 10:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$477 | 50 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$87 | 52 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$186 | 54 HOLD |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$405 | 55 HOLD |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$81 | 59 HOLD |
